A phase II study of Chinese patients (pts) treated with nab-paclitaxel (nab-P) plus gemcitabine (Gem) for metastatic pancreatic cancer (MPC)

被引：0
|
作者：
Shen, Lin
Yu, Xianjun
Hao, Jihui
Wang, Liwei
Pan, Hongming
Han, Guohong
Xu, Jian-Ming
Zhang, Yanqiao
Yang, Shujun
Chen, Jia
Ying, Jieer
Dai, Guanghai
Li, Mingyu
Begic, Damir
Lu, Brian D.
Xu, Ruihua
机构：
[1] Beijing Canc Hosp, Beijing, Peoples R China
[2] Fudan Univ, Shanghai Canc Ctr, Shanghai 200433, Peoples R China
[3] Tianjin Canc Hosp, Tianjin, Peoples R China
[4] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Shanghai 200030, Peoples R China
[5] Sir Run Run Shaw Hosp, Hangzhou, Zhejiang, Peoples R China
[6] Fourth Mil Med Univ, Dept Liver Dis & Digest Intervent Radiol, Xijing Hosp Digest Dis, Xian 710032, Peoples R China
[7] Acad Mil Med Sci, Hosp 307, Ctr Canc, Beijing, Peoples R China
[8] Harbin Med Univ, Affiliated Hosp 3, Harbin, Peoples R China
[9] Henan Canc Hosp, Zhengzhou, Peoples R China
[10] Jiangsu Canc Hosp, Nanjing, Jiangsu, Peoples R China
[11] Zhejiang Canc Hosp, Dept Chemotherapy, Hangzhou, Zhejiang, Peoples R China
[12] Peoples Liberat Army, Gen Hosp, Beijing, Peoples R China
[13] Celgene Corp, Summit, NJ USA
[14] Celgene Corp, Madison, NJ USA
[15] Sun Yat Sen Univ, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期
关键词：
D O I：
10.1200/jco.2016.34.4_suppl.327
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
327
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Tumor reduction in pancreatic versus metastatic sites in a randomized phase III study (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone.
    Kunzmann, Volker
    Ramanathan, Ramesh K.
    Goldstein, David
    Penenberg, Darryl Neil
    Ferrara, Stefano
    Lu, Brian
    Von Hoff, Daniel D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [32] NCCTG phase II trial N0531of weekly nab-paclitaxel (nab-p) in combination with gemcitabine (gem) in patients with metastatic breast cancer (MBC)
    Roy, V.
    LaPlant, B. R.
    Gross, G. G.
    Bane, C. L.
    Palmieri, F. M.
    Perez, E. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [33] Gemcitabine (G) plus nab-paclitaxel (nab-P) plus chemoradiation (CRT) in locally advanced pancreatic cancer (LAPC)
    Olowokure, Olugbenga Olanrele
    Bedoya, Ivan Dario
    Mierzwa, Michelle Lynn
    Torregroza, Maria Patricia
    Dwivedi, Alok Kumar
    Wang, Jiang
    Smith, Milton T.
    Schmulewitz, Nathan
    Kucera, Stephen
    Choe, Kyuran Ann
    Ristagno, Ross
    Rudich, Steven
    Sussman, Jeffrey J.
    Ahmad, Syed A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [34] A phase II study of vismodegib, a hedgehog (Hh) pathway inhibitor, combined with gemcitabine and nab-paclitaxel (nab-P) in patients (pts) with untreated metastatic pancreatic ductal adenocarcinoma (PDA)
    De Jesus-Acosta, Ana
    O'Dwyer, Peter J.
    Ramanathan, Ramesh K.
    Von Hoff, Daniel D.
    Maitra, Anirban
    Rasheed, Zeshaan
    Zheng, Lei
    Rajeshkumar, N. V.
    Le, Dung T.
    Hoering, Antje
    Bolejack, Vanessa
    Yabuuchi, Shinichi
    Laheru, Daniel A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [35] Expression of SPARC and response to nab-paclitaxel (nab-p) in patients (pts) with metastatic breast cancer (MBC)
    Schneeweiss, Andreas
    Aigner, Julia
    Smetanay, Katherina
    Schuetz, Florian
    Sohn, Christof
    Kriegsmann, Mark
    Jaeger, Dirk
    Zorn, Markus
    Bachinger, Andreas
    Sinn, Hans-Peter
    Marme, Frederik
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [36] Phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P plus Gem) versus gemcitabine (Gem) alone for patients with resected pancreatic cancer (PC): Outcomes by geographic region.
    Reni, Michele
    Riess, Hanno
    O'Reilly, Eileen Mary
    Park, Joon Oh
    Hatoum, Hassan
    Saez, Berta Laquente
    Salminen, Tapio
    Oettle, Helmut
    Lopez, Rafael
    Dowden, Scot D.
    Karthaus, Meinolf
    Tabernero, Josep
    Van Cutsem, Eric
    Philip, Philip Agop
    Goldstein, David
    Berlin, Jordan
    Tempero, Margaret A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [37] Impact of elevated bilirubin on eligibility of metastatic pancreatic cancer (MPC) patients (pts) for nab-paclitaxel plus gemcitabine (N plus G).
    Lau, Sally C.
    Peixoto, Renata
    Cheung, Winson Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [38] Phase II study of pirfenidone combined with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer
    Guo, Guifang
    Li, Shengping
    Mao, Yize
    Yang, Qiuxia
    Yao, Zehui
    Wang, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [39] Updated analysis of weekly nab-Paclitaxel (P) plus Gemcitabine (G) with metastatic pancreatic cancer (MPC): Phase I/II trial
    Omuro, Yasushi
    Ueno, Hideki
    Ikeda, Masafumi
    Ueno, Makoto
    Mizuno, Nobumasa
    Ioka, Tatsuya
    Nakajima, Takako
    Furuse, Junji
    ANNALS OF ONCOLOGY, 2015, 26 : 88 - 89
  • [40] Optimized economic evaluation for the United States (US) of nab-paclitaxel plus gemcitabine (NAB-P plus GEM) FOLFIRINOX (FFX), and gemcitabine (GEM) as first-line treatment for metastatic pancreatic cancer (mPDA)
    Gharaibeh, Mahdi
    McBride, Ali
    Bootman, J. Lyle
    Patel, Hitendra
    Abraham, Ivo
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345